Trials / NCT02464436
Safety and Tolerability of hRPC in Retinitis Pigmentosa
Status unknown Phase 1 / Phase 2 Gene therapy, Cell therapy, Retinal implant
- Sponsor
- ReNeuron Limited
- Treatment
- hRPC
- Gene
- Not stated
- Conditions
- Retinitis Pigmentosa
- Ages
- 18 Years to no upper limit
- Enrollment
- 29 participants
- Started
- 2015-12
- Main results expected
- 2022-06
- Results posted
- Not yet
- Record last updated
- 2023-07-06
What the study is testing
hRPC is a cell therapy for retinitis pigmentosa. This is a first-in-human, dose escalation study in which participants with retinitis pigmentosa will receive a single subretinal injection of hRPC cells in one eye to evaluate safety and tolerability.
Participants will be followed for two years to evaluate the safety and tolerability of hRPC Additional testing will seek to establish any preliminary efficacy from hRPC.
Where it runs
Spain (1)
- Institut de la Màcula, Barcelona
United Kingdom (1)
- Oxford Eye Hospital, Oxford
United States (3)
- Retinal Research Institute, Phoenix, Arizona
- Massachusetts Eye and Ear Infirmary, Boston, Massachusetts
- Oregon Health and Science University, Portland, Oregon